Share Name Share Symbol Market Type Share ISIN Share Description
Premier Vet Grp LSE:PVG London Ordinary Share GB00BSZLMS59 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 138.00p 120.00p 139.00p - - - 84 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 2.3 -1.6 -17.5 - 20.57

Premier Vet Grp (PVG) Latest News

More Premier Vet Grp News
Premier Vet Grp Takeover Rumours

Premier Vet Grp (PVG) Share Charts

1 Year Premier Vet Grp Chart

1 Year Premier Vet Grp Chart

1 Month Premier Vet Grp Chart

1 Month Premier Vet Grp Chart

Intraday Premier Vet Grp Chart

Intraday Premier Vet Grp Chart

Premier Vet Grp (PVG) Discussions and Chat

Premier Vet Grp Forums and Chat

Date Time Title Posts
23/10/201617:10DOG AND CAT OWNERS 372

Add a New Thread

Premier Vet Grp (PVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
24/10/2016 16:35:16138.00174240.12UT
View all Premier Vet Grp trades in real-time

Premier Vet Grp (PVG) Top Chat Posts

Premier Vet Grp Daily Update: Premier Vet Grp is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker PVG. The last closing price for Premier Vet Grp was 138p.
Premier Vet Grp has a 4 week average price of 135.83p and a 12 week average price of 139.27p.
The 1 year high share price is 180p while the 1 year low share price is currently 0p.
There are currently 14,907,433 shares in issue and the average daily traded volume is 4,492 shares. The market capitalisation of Premier Vet Grp is £20,572,257.54.
hydrus: Thanks pet lover that's interesting insight. Some institutional buying would certainly boost the price quite quickly because of the low number shares in issue. Would be quite tricky to say get to 5% of the company. I am expecting mr uppal to seek to reduce his holding at some point because he has such a big stake. Can't see him doing that until the share price reflects the prospects fully, might have to wait a year or two but I'm sure that won't be a problem.
hydrus: The company is investing for the long term. I agree that non-dilution is a big positive, which is why having Directors own a large part of the company is an advantage. They don't want to get diluted either.The company will lose money this year and I'm pretty sure same again next year. Anyone looking for profitability quickly should think again. The revenue growth however will give some insight into where things are heading. This year might be 40% plus growth. Next year we shall see but with this years plans sold fully kicking in plus some growth it could be 50-100% revenue growth. I think we should be between 140,000 and 150,000 plans by end of September. This might increase to 250,000 by end of September next year if USA kicks in well. In terms of the share price - If the business performs well the share price will follow. The shares might not do that much over the next year or so until it becomes clear that profits are not far away. Alternatively investors may realise that with the high revenue growth there is something exciting here and buy in. I do not worry about the share price though.
pet lover: Lunch Hour 🍴. I have been sent a report on BOO results yesterday from a mate of mine who is a fan of them.BOO sell fashion on the Internet to youngsters they are growing sales at 40% //////////////////////////////////////////////////////////////////////////////////////////////// # One of the reasons for the incredible share price surge is that boohoo offers investors something which seems terribly difficult to find right now: organic growth. Without the need to acquire other businesses or leverage up, boohoo has been able to use internally generated profit to ramp up its marketing spend and its stock turnover in a virtuous cycle of accelerated growth. Sales increased by 27% and 39% in FY 2015 and FY 2016, respectively, and the company has guided this morning that it believes sales growth for FY 2017 (the year ending February) will be in the range of 28%-33% (previous guidance was 25%-30%). That will push sales into a £250 million-£260 million range. Going on past margins, that would generate a gross profit of around £150 million and it will then be a question of how much operational leverage can be generated through the achievement of relatively fixed costs. Today’s statement is bullish on that front, saying that operational leverage will result in improved EBITDA margins. If marketing and other expenses did not increase against last year, then about £50 million of operating profit would be left over. Interest is negligible, so pre-tax profit would be around that level. Marketing expenses are the great imponderable with this business, however: it needs to spend a lot on marketing to seize market share and to build the power of its own brands. Brokers are currently anticipating that after increased costs, c. £21 million of pre-tax profit will be left. But I expect that they will need to revise these forecasts materially higher after today’s statement. It feels strange to say this for a company on a trailing PE ratio of 72, but I suspect that boohoo is not wildly overpriced at this level. Given today’s update, perhaps it can generate, on an after-tax basis, something closer to £20 million in profits this year.# //////////////////////////////////////////////////////////////////////////////////////////////// The reporter points out that even at this price BOO shares might be good value at £800M market cap for £20M of profit this year. It's its perceived growth rate in the next few years that is still attracting investors at today's sky high price. The hound and I don't want to buy stocks in companies like BOO after the growth rate has been spotted by the wider market hundreds of fund managers and the lady next door. BOO and PVG have a few things in common and a few that are not. Both have the attraction of very fast organic growth.Both have markets for their products. They are also proven although PVG is reinvesting its cash this current year at the expense of any profit. PVG have one edge over BOO by way of its recurring revenues.BOO has nothing to fall back on if they hit a sales blip over a period of a few months. PVG is valued at £20M today but it's growth trajectory over the next five years could see it make £20M of profits in five years time. Those profits could be a great deal more stable than any BOO ever produce.Margins are 97% on PVG'S pet plans BOO'S are 60% of sales. Is it pie in the sky to think PVG could be worth £800M.? In short no I don't think it is. 10,000 vets signed to date selling 1.4 plans a week each @20.00 a time is £60M in sales by year 4. Year 5 only gets a third of the income the rest goes into year 6. Total after 5 years is £65M in sales. That would leave £45 million for other costs.This assumes no more vets are signed up which to be frank is silly. Forecasting is terribly difficult at the best of times and five weeks is a long time let alone 5 years. Since sales growth at PVG is running at around 100% a year and might increase on that shareholders might start to be rewarded sooner rather than later. Any share price that doubles in five years is paying you 20% a year a terribly good return. At £800M market cap in five years you could beat that no less than 38 times. Now theirs a thought.Time for ☕️ then back to work.
pet lover: Today's contract win increases PVG'S vets under contract by a factor of C: 9.6 times. Over the period October 2017 - 2022 plan sales should rise by the same amount.Today so far the companies stock price has risen by 25%. Clearly the market demands a very large discount to what may or may not happen in the years ahead.The share price movement since 8AM has now factored in 2% of that 9.6 times. Over the next five years all being equal that should disappear and the shares should in theory at least stand in 9.6 times higher than today due to this one contract. It will be interesting to look back in 2022.Todays 2% is the start of a revaluation of PVG.Give it a month or two and I would expect the share price to track towards a total 10% up from 2%.(90% discount to today's news). In pound shillings and pence that equals over another pound on the share price.Everything this company does seems extremely professional it might now be the time to appoint a descent broker and get some numbers out in the open.The growth rate starting in October when all these recent contracts kick in should see me and the hound putting the V sign up to the area manager at work with a bit of luck.🌞ӽ74;
hydrus: Lomax - I may be being optimistic about profits it's hard to know. We are estimating the fee per plan PVG gets and also as this agreement is with a veterinary supply company they will take a slice. However it is evident that a) there is nothing better on the market as massive US companies are leaping on the pet plan product like a tramp on chips b) PVG is worth considerably more than a paltry £25m.The quality of recurring revenues is another positive here as Petlover points out. I can see PVG being acquired by I just hope it's a few years down the line when the share price is considerably further north than it is now.
ginger_ninja1: Cracking news today, if the share price moves 10% with every contract announcement I'm going to be a rich man. Keep them coming PVG.
ginger_ninja1: From a technical prospective the last weeks share price moves have been some what strange.The market bid 25,000 at £1.25P most of last week and a smaller 3,000 at £1.38P . A few shares were on offer at 148P. Yesterday, after results and light selling the price was slammed down even though buys far outnumbered sells. Some buying this morning has seen the bid/ offer prices move up. A cynic could be correct in thinking yesterday's action was the work of the market jobbers trying to get some stock at low prices.
pet lover: Rip off Britain the BBC said bright sunshine we've had rain and buckets of it. I found this yesterday. It's two years old but of great interest as it refers to the fastest growth shares on the secondary market at the time. PVG is not on that market, being fully listed but for growth purposes it's a great illustration. I invite you to read it. The hound and I have come to these conclusions. If this is the best of the bunch then I don't think I would want to be invested in all the other AIM stocks. For long term growth I would rule out the brick-maker and the Gem stone miner both suffer from constant pricing pressure. When you remove them,growth from the other 3 doesn't look that appealing to me. I now refer back to PVG and it's possible growth rate of doubling sales from 80,000 to 160,000 this financial year then doing the same next and again in the following year. If PVG can be seen to be doing this and costs are kept under tight control I am convinced the shares will eventually get noticed by the wider market and respond accordingly. The recurring revenues should ensure growth continues be it at a slower rate for years to come. companies By Lee Wild | Fri, 21st November 2014 - 16:47 Share this AIM's fastest growing companies There are hundreds of companies on AIM. Some are tiny and lose lots of money; others like ASOS (ASC) are worth over £2 billion and make substantial profits. But the junior market is the home of the growth stock, and some businesses have been growing earnings at breakneck speed. After screening the entire small-cap sector, we've uncovered the fastest-growing companies and give our take on prospects. Of course, it's no surprise to hear about growth on AIM. That's typically reflected in high price/earnings (P/E) ratios and very little by way of income generation (see table). Yet many of the top five growth companies we've identified appear not to be trading on vastly overinflated valuation multiples despite the potential growth on offer. Clearly, there is always risk associated with this type of company. Growth assumptions are baked into valuations and any earnings-miss will certainly be punished. However, hard work done improving margins and repairing balance sheets after the financial crisis laid the foundation for a profits recovery, and improving economic conditions generate an obvious benefit. True, 2014 has not been quite the cakewalk many experts had predicted. Europe, the UK's biggest trading partner, remains a basket case and growth elsewhere, especially in China, has been more pedestrian than anticipated. "Despite setbacks, an uneven global recovery continues," said the International Monetary Fund (IMF) recently. It's why the organisation has just revised down global growth forecasts to 3.3%. Yet, while geopolitical risk remains, and stockmarkets look certain to remain volatile, economists predict 3.8% growth in 2015. Even the eurozone should improve. Highly accommodative monetary policy, including historically low interest rates, should underpin a recovery. So, which of AIM's high-flyers stand to benefit from this improved prognosis and have, perhaps, been overlooked by growth-hungry investors? Michelmersh Brick Holdings Earnings fell at Michelmersh Brick (MBH) in 2013, but first-half results this year were better-than-expected and forced Cenkos Securities to upgrade forecasts. Higher brick prices mean adjusted earnings per share (EPS) are now tipped to rocket by 1,000% in 2014, up from 0.2p to 2.2p. That’s more than double the 2012 figure, too. Next year, it's back down to earth, although forecast growth of 25% is not to be sniffed at, and average forecast growth for the two years is a stunning 511%. Company Ticker Price (p) Mkt Cap (£m) Est EPS growth (Year 1) Est EPS growth (Year 2) Est EPS growth (Year 3) Forward PE ratio % price change (3 months) % price change (1 year) Dividend yield (%) Michelmersh Brick Holdings MBH 61 49 1,000 23 - 28 -6 13 - Greenko GKO 149 149 217 56 - 22 -14 -3 - Havelock Europa HVE 19 19 158 41 23 10 -17 2 - Mytrah Energy MYT 73 73 141 69 39 12 -17 -10 - Gemfields GEM 50 50 136 104 38 20 5 29 - Source: S&P Capital IQ, Investec Securities, Numis, Cenkos, finnCap, Oriel, Westhouse MBH's share price is underpinned by investment land valued at 26p per share. Strip that out and Michelmersh shares trade on just 16 times current-year forecast earnings, dropping to 13 in 2015. That's a discount to the Construction & Materials sector. Unfair, says Cenkos: We would argue that MBH should trade at a premium to this operating in an industry impacted by a supply demand deficit with high barriers to entry preventing significant additions to supply capacity. There is scope for a sustained recovery underpinned by political pressure to resolve the UK housing shortage and the minor £3,000 cost of bricks for the average UK house is indicative that there is scope for sustained price increases. Gemfields Precious stones miner Gemfields (GEM) is the only company in the list of super-growth firms expected to double earnings for the next two years. Look for EPS growth of 136% in the year to June 2015, a further 104% surge in 2016, and 38% the following year, says Investec Securities. At its recent auction in Lusaka, Zambia, the company auctioned 0.598 million carats of higher quality emeralds from its Kagem mine. That generated revenue of $34.9 million, the second highest achieved at higher quality auctions to date. An average value of $65.89 per carat is a record for Kagem stones. And look out for another ruby auction next month. A maiden sale in August of stones from the Montepuez mine raised $15.5 million. That more than covered all investment in the asset, said Investec. We know Gemfields has ramped up production since, so there are high hopes. A strong dollar means the broker thinks the shares are worth 61.1p. Havelock Europa If Havelock Europa's crucial fourth quarter goes to plan, the interior designer will make a £0.9 million profit in 2014, up from £0.6 million the year before. Half-year results were certainly encouraging. Havelock typically loses money in the first half and broker Oriel Securities thinks it will generate almost two-thirds of sales during the final six months of the year. In 2015, Oriel reckons Havelock could make £1.3 million. It's diversifying revenues and net debt is falling. Overseas sales are rising, too, and management expects an uptick in demand from the high street banks and retailers, student accommodation and the education sector. Clearly, the weak education market is worrying investors and the share price has fallen since September's results, but Oriel sticks with its 30p target price. Greenko Greenko (GKO) builds and runs clean energy projects in India, and it’s clearly big business. In a recent first-half update, the company increased power generation by 89% to 1,225 gigawatts (GWh), which, it said, should grow first-half revenue by over 120% cash profit by about 130%. "As the Indian energy market becomes increasingly favourable towards hydro and wind power, we remain very optimistic about the sustainability of our solid operational and financial performance," said boss Anil Chalamalasetty. Installed capacity increased by 136 megawatts (MW) to 697 MW, and Greenko says it’s still on track for its operational portfolio to exceed 1,000 MW in 2015. That’s why house broker Arden Partners has pencilled in adjusted EPS growth of 217% for the year to March 2015. The company has also refinanced its Standard Chartered debt on better terms following a $125 million investment from EIG Global Energy Partners. Says Arden: The back-end loaded structure of the interest payments works well with renewable assets and further de-risks Greenko's finances following last month's bond issue. This and the likely upward pressure on electricity prices from the re-auctioning of coal mines puts Greenko in a strong position that has not been reflected in a relatively flat share price. Mytrah Energy Mytrah Energy (MYT), the India-based power company, has raised $70 million of new debt to cover an existing mezzanine facility and to develop new wind power projects currently in the pipeline. Half-year results published in September revealed a slow start to the wind season, although conditions have picked up and, according to Investec, full-year numbers are still achievable. That keeps Mytrah on track to make a $19 million profit this year and $31 million in 2015. Of course, there are risks here, but "recent political and economic developments play to the advantage of the renewable producers," reckons Investec, which repeats its 165p target price. One-year wonders As we pointed out in October, this year has been one of rapid growth for Proactis (PHD). The spend control software firm said last month that earnings rocketed by 53% in the year to July after surging by 120% in 2013. FinnCap predicts the'll grow by 135% in the year to 2015. Growth slows to a much more modest 8% the year after, but despite tripling already this year, finnCap reckons even its recently-raised target price of 115p may be conservative. Christie (CTG) is expected to double adjusted pre-tax profit to £2.9 million and EPS to 8.38p in 2014, according to Charles Stanley. After that, it's more modest progress of 6% and 9% respectively. Plus500 (PLUS) is slated to double profit to $138 million and grow EPS by 94% to 91 US cents, says Numis Securities. In 2015, that slows to 15%, then 13% the year after. Brady (BRY) will ramp up adjusted pre-tax profit by 96% to £4.9 million, if Panmure Gordon has got its sums right. It’s 16% and 14% in subsequent years. The finishing line is in sight for hostel operator Safestay (SSTY), spun out of Safeland in May. It's on track to grow EPS by 122% to 4.8p, although there's a pause next year before a resumption of double-digit growth in 2016. Elsewhere, skin-focused pharma firm Sinclair IS Pharma (SPH) is tipped to grow earnings by 37% in the year to June 2015 and 53% the following year. That's impressive, and a forward PE ratio of less than 17 is an unfair discount to the sector. Directors certainly think so. They've just spent over £200,000 on shares in the company. And finally, James Cropper (CRPR), the speciality paper firm which provides the material for Remembrance Day poppies, has just doubled half-year adjusted pre-tax profit. New products, cost-cutting and capital investment underpin bullish growth forecasts, says Westhouse. Average annual forecast EPS growth of 28% over the next three years appears not to be reflected in a forward earnings multiple of 12, dropping to just 9.3 in 2015. This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
pet lover: Netcurtains: PVG is not a trading stock nor will it be paying dividends for years. It's attractive to those investors who are looking for low scale risk while at the same time being exposed to 100% turnover growth.The nature of the companies recurring revenues is the icing on the cake. This should produce solid share price gains over the long term so long as costs are kept under control. The directors have proved themselves buying the vets turning them around and then cashing in.The share price graph since the RTO has always been extremely volatile not helped by current market sentiment.Most companies struggle to grow turnover at 20% here we look like doing 5 times that. For the above reasons the hound and I don't think your share certificates will be in that draw for many months yet alone years.😯
pet lover: Getting lighter in the mornings at last so can walk the hound with less chance of us being run over. PETS issued a trading statement this week that the market warmed to.Shop sales growth was just 1.7% but Services dog grooming and so on caught the markets eye expanding by 27%. The stock has had a good run since.This draws me back to PVG. Can't help thinking the business model now the vet practices have been booted out of the door is rather good.For starters it's simple with clean edges.Recurring revenues and very high margins come next.Compertition is weak in the UK that has enabled PVG to gain a large slice of the available veterinary practices from a standing start four years ago.Europe from my limited investergations is years behind the UK and offers a real opportunity for rapid growth. I would have thought the vet health plan could be designed,IT within the practice sorted and staff trained all within ten weeks.After that the cash starts to roll in at 1/12th of the yearly subscription.The FD knows each day how sales are doing against targets and with the aid of the other directors can adjust the growth rate at the front end of the business with absolute confidence.Sales growth will innatialy dictate the share price of PVG.Amazon is a prime example of this where investors have yet to see any meaningful profits yet the share price reflects megga returns.
Premier Vet Grp share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20161025 13:49:07